Genetically engineered immune cells, which express at least two metabolism modulating polypeptides and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered immune cells for inhibiting cells expressing a target antigen in a subject in need thereof.

A population of genetically engineered T cells, comprising a disrupted protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene and optionally a disrupted TRAC gene, a disrupted 2M gene, and/or a disrupted CD70 gene. Also provided herein are methods for making such genetically engineered T cells and therapeutic uses thereof.

This invention is directed to chimeric antigen receptors and cells comprising the same, wherein the cells further secrete monoclonal antibodies locally at a tumor site.

The present invention provides a method for preparing an immune cell, such as a tumor-associated antigen-specific T cell (TAA-T cell), which is engineered with an IL-8 receptor. The present application also provides an immune cell, such as a T cell which is tumor-associated antigen-specific and is engineered with an IL-8 receptor. Immune cells (such as T cells) are genetically engineered to bind to IL-8 in the tumor environment that can serve as a potential strategy to improve immunotherapy for pediatric solid tumors.